The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Open accessAbstract
BACKGROUND: Although it is generally accepted that lowering elevated serum levels of low-density lipoprotein (LDL) cholesterol in patients with coronary heart disease is beneficial, there are few data to guide decisions about therapy for patients whose primary lipid abnormality is a low level of high-density lipoprotein (HDL) cholesterol. METHODS: We conducted a double-blind trial comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less. The primary study outcome was nonfatal myocardial infarction or death from coronary causes. RESULTS: The median follow-up was 5.1 years. At one year, the mean HDL cholesterol level was 6 percent higher, the mean triglyceride level was 31 percent lower, and the mean total cholesterol level was 4 percent lower in the gemfibrozil group than in the placebo group. LDL cholesterol levels did not differ significantly between the groups. A primary event occurred in 275 of the 1267 patients assigned to placebo (21.7 percent) and in 219 of the 1264 patients assigned to gemfibrozil (17.3 percent). The overall reduction in the risk of an event was 4.4 percentage points, and the reduction in relative risk was 22 percent (95 percent confidence interval, 7 to 35 percent; P=0.006). We observed a 24 percent reduction in the combined outcome of death from coronary heart disease, nonfatal myocardial infarction, and stroke (P< 0.001). There were no significant differences in the rates of coronary revascularization, hospitalization for unstable angina, death from any cause, and cancer. CONCLUSIONS: Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level. The findings suggest that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, the mean reduction in plasma triglyceride concentration in the fibrate trials was only 20 mg/dL to 50 mg/dL, a fraction of what would be needed to significantly reduce the risk of major vascular events within a shortterm trial.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [30]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Treatment with gemfibrozil versus placebo reduced the primary endpoint of death or nonfatal MI by 32% (P = 0.004), mortality by 41% (P = 0.02), and stroke by 40% (P = 0.046).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence supporting the prescription of fibrates for cardiovascular prevention remains debated.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fibrates decrease triglyceride levels by 30 -50% and sometimes increase HDL cholesterol (165-168).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A sub study was conducted on patients with diabetes participating in the VA-HIT Trial (n=627) compared to those without diabetes (n=142). Following 5 years of treatment with gemfibrozil the investigators observed an average reduction of TG levels by 31% and a corresponding increase in HDLC of 6%. More importantly, these changes were associated with a, statistically significant 22% reduction in”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [72]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical and epidemiological studies have demonstrated that triglyceride (TG) elevation is an independent risk factor for increased cardiovascular (CV) events”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Epidemiological, biological, and genetic studies have provided robust evidence of a strong association between elevated TG levels and higher rates of CV events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous fibrate studies in subjects with diabetes10,11 or in those without diabetes13–15 did not address the role of such drugs in patients receiving statin therapy.”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“The ACCORD, LEADER and VA-COOP trials could not confirm that fibrates reduce the incidence of MACE at a 5% significance level, whilst a significant MACE reduction was observed in the FIELD and VA-HIT trials [91–94].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“Studies to date have not demonstrated an overall benefit of fibrates for reduction of cardiovascular or total mortality (165-169).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [166]
The cited source says what the claim attributes to it.
In the citing paper
“For example, the VA-HIT Trial, with a total of 2,531 men with a history of CHD who had low HDLC levels (mean, 32 mg/dl) and low LDLC levels (mean, 111 mg/dl), assigned subjects to receive either 1,200 mg/day of gemfibrozil or placebo. After a 5 year follow-up, treatment with gemfibrozil resulted in a significant 22% reduction in the combined incidence of nonfatal myocardial infarction (MI) and CHD”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“However, randomized data from large outcome studies across broad populations regarding pharmacological TG lowering and effect on CV outcomes have been mixed (Table 4).1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Again, there was no significant difference in allcause mortality”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“The results of this study may also help to explain why prior randomized trials evaluating fibrates, which lower plasma triglyceride levels at least partially through the LPL pathway, have failed to consistently demonstrate that lowering triglyceride levels reduces the risk of cardiovascular events.[29][30][31][32][33]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, TG reduction lowers several inflammatory markers associated with CV risk, and subgroup and post hoc analyses of outcome studies suggest possible reductions in major CV events with TG‐lowering therapy.3, 4, 5, 6, 7, 8, 9, 10, 11”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Additionally, qualitative changes in LDL cholesterol may be present in the form of small, dense LDL particles which are more atherogenic and may be associated with higher risk of CVD [58-60].”
From The case for low carbohydrate diets in diabetes management (2005) · cites this paper as [60]
In the citing paper
“As monotherapy, fibrates likely reduce ASCVD risk.43–45”
From Clinical review on triglycerides (2020) · cites this paper as [45]
In the citing paper
“In the Helsinki Heart Study (HHS) [4] and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) [5], administration of gemfibrozil significantly reduced CV event rate, the primary endpoints of the trials.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [5]
In the citing paper
“In some studies, an increase of patient-reported neurocognitive effects has been described [293].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [293]
In the citing paper
“However, the data on other outcome parameters have remained equivocal.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“The data from these trials have shown consistent decreases in the rates of non-fatal MI (although often as a result of post-hoc analyses), the effect being most robust in subjects with elevated TG/low HDL-C levels.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“The clinical benefits of fibrates in monotherapy are primarily illustrated by four prospective, randomized, placebo-controlled, clinical trials: Helsinki Heart Study (HHS), Veterans Affairs Highdensity lipoprotein Intervention Trial (VA-HIT), Bezafibrate Infarction Prevention study (BIP), and FIELD.124 -127”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [125]
In the citing paper
“Although the Helsinki Heart Study reported a significant reduction in CVD outcomes with gemfibrozil, neither the FIELD nor the ACCORD study showed a reduction in total CVD outcomes.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [266]
In the citing paper
“The results of ESTABLISH642), JAPAN-ACS643), the ZEUS study644), and PRECISE-IVUS645) have shown that in cases stratified into a high-risk category even in secondary prevention, such as ACS or ACS complicated by DM, controlling the LDL-C at a target level of < 70 mg/dL is useful for plaque regression.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [645]
In the citing paper
“It was reported in the recent PRECISE-IVUS study that decreasing the LDL-C level to < 70 mg/dL using a combination of statin and ezetimibe resulted in a marked plaque volume regression in patients with ACS, compared to those who were treated with statins only645).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [645]
In the citing paper
“Gemfibrozil has been shown to decrease rates of CVD events in subjects without diabetes (195,196) and in the diabetic subgroup in one of the larger trials (195).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [195]
In the citing paper
“However, additional adjustment for HDL-C and the ratio of apo B to apo AI decreased the predictive ability of on-treatment triglyceride levels, and further adjustment for baseline glucose, BMI, hypertension, T2DM, and smoking eliminated the association.501”
From Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association (2011) · cites this paper as [501]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Mantel N, 1966, Cancer Chemother Rep, 3, 163
Cited by
Sorted by citations
Items 601–700 of 1,017
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
Lara, J. J., Economou, M., Wallace, A. M., Rumley, A., Lowe, G. D. O., Slater, C., CASLAKE, M. J., Sattar, N. A., & Lean, M. E. J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.06.018 · Cited by 89
Gegick, C. G., & Altheimer, M. D. (2001) · Endocrine Practice · doi:10.4158/ep.7.3.162 · Cited by 89
Electron beam tomography and National Cholesterol Education Program guidelines in asymptomatic women
Hecht, H. S., & Superko, H. R. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01211-6 · Cited by 88
Niacin dosing: Relationship to benefits and adverse effects
Capuzzi, D. M., Morgan, J. M., Brusco, O. A., & Intenzo, C. M. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0096-y · Cited by 88
Treatment of hypertension in peripheral arterial disease
Lane, D. A., & Lip, G. Y. H. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003075.pub3 · Cited by 91
Guyton, K. Z., Chiu, W. A., Bateson, T. F., Jinot, J., Scott, C. S., Brown, R. C., & Caldwell, J. C. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0900758 · Cited by 89
Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2006) · Cardiovascular Diabetology · doi:10.1186/1475-2840-5-20 · Cited by 90
High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients
Bruckert, É., Baccara‐Dinet, M. T., McCoy, F., & Chapman, J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x74871 · Cited by 88
Murad, M. H., Hazem, A., Coto-Yglesias, F., Dzyubak, S., Gupta, S., Bancos, I., Lane, M. A., Erwin, P. J., Berglund, L., Elraiyah, T., et al. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-2 · Cited by 87
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 88
Reverse cholesterol transport: High-density lipoprotein’s magnificent mile
Toth, P. P. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0010-5 · Cited by 87
Rensen, P. C. N., van Leeuwen, S. H., Sliedregt, L. A. J. M., van Berkel, T. J. C., & Biessen, E. A. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049481d · Cited by 87
Ganse, E. H. V., Laforest, L., Alemao, E., Davies, G., Gutkin, S. W., & Yin, D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59139 · Cited by 87
The triglyceride–high-density lipoprotein axis: An important target of therapy?
Szapary, P. O., & Rader, D. J. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.037 · Cited by 87
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86
Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Collino, M., Patel, N. S. A., & Thiemermann, C. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708090924 · Cited by 87
Treatment of metabolic syndrome
Wagh, A., & Stone, N. J. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.2.213 · Cited by 87
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2011) · Clinical Lipidology · doi:10.2217/clp.10.84 · Cited by 88
Self-citationPlutzky, J. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0067-3 · Cited by 87
Pluim, B. M., Staal, J. B., Marks, B. L., Miller, S., & Miley, D. (2007) · British Journal of Sports Medicine · doi:10.1136/bjsm.2006.034967 · Cited by 98
Babaev, V. R., Ishiguro, H., Ding, L., Yancey, P. G., Dove, D. E., Kovacs, W. J., Semenkovich, C. F., Fazio, S., & Linton, M. F. (2007) · Circulation · doi:10.1161/circulationaha.106.684704 · Cited by 91
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 88
Prevention of the complications of diabetes.
Vinik, A. I., & Vinik, E. J. (2003) · PubMed · Cited by 85
McGrowder, D. A., Riley, C. K., Morrison, E., & Gordon, L. (2010) · Cholesterol · doi:10.1155/2011/496925 · Cited by 85
Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 88
Pluim, B. M., Groppel, J. L., Miley, D., Crespo, M., & Turner, M. S. (2017) · British Journal of Sports Medicine · doi:10.1136/bjsports-2017-098623 · Cited by 90
Kjeldsen, S. E. (2004) · Heart Drug · doi:10.1159/000076263 · Cited by 85
Pharmacogenomics of cholesterol-lowering therapy
Schmitz, G., & Langmann, T. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.012 · Cited by 86
The Metabolic Syndrome: A Practical Guide to Origins and Treatment: Part II
Wilson, P. W. F., & Grundy, S. M. (2003) · Circulation · doi:10.1161/01.cir.0000089506.12223.f1 · Cited by 84
Search for an Optimal Atherogenic Lipid Risk Profile: From the Framingham Study
Nam, B., Kannel, W. B., & D’Agostino, R. B. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.055 · Cited by 84
Torcetrapib impairs endothelial function in hypertension
Simic, B., Hermann, M., Shaw, S., Bigler, L., Stalder, U., Doerries, C., Besler, C., Lüscher, T. F., & Ruschitzka, F. T. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr348 · Cited by 86
The Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 86
High-Density Lipoprotein Cholesterol and Coronary Heart Disease
Young, C. E., Karas, R. H., & Kuvin, J. T. (2004) · Cardiology in Review · doi:10.1097/01.crd.0000097140.29929.8a · Cited by 84
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Triglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 87
Remick, J. S., WEINTRAUB, H. S., Setton, R. A., Offenbacher, J., Fisher, E. A. A., & Schwartzbard, A. Z. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31816b43d3 · Cited by 83
Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression
Kaur, N., Pandey, A. K., Negi, H., Shafiq, N., Reddy, S., Kaur, H., Chadha, N., & Malhotra, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094585 · Cited by 83
Shaish, A., Harari, A., Hananshvili, L., Cohen, H., Bitzur, R., Luvish, T., Ulman, E., Golan, M., Ben‐Amotz, A., Gavish, D., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.12.004 · Cited by 83
Dieta vegetariana e níveis de colesterol e triglicérides
Biase, S. G. D., Fernandes, S. F. C., Gianini, R. J., & Duarte, J. L. G. (2007) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2007000100006 · Cited by 83
Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus
Woodman, R. J., Chew, G. T., & Watts, G. F. (2005) · Drugs · doi:10.2165/00003495-200565010-00003 · Cited by 83
Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials
Farmer, J. A. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0013-2 · Cited by 83
Simes, R. J. (2002) · European Heart Journal · doi:10.1053/euhj.2001.2775 · Cited by 84
Calza, L., Manfredi, R., & Chiodo, F. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00115-8 · Cited by 83
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
Bilz, S., Wagner, S., Schmitz, M., Bedynek, A., Keller, U. B., & Demant, T. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300309-jlr200 · Cited by 83
Myopathy with statin–fibrate combination therapy: clinical considerations
Jacobson, T. A. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.151 · Cited by 82
Use of Fibrates in the United States and Canada
Jackevicius, C. A. (2011) · JAMA · doi:10.1001/jama.2011.353 · Cited by 82
Fibrates in Combination With Statins in the Management of Dyslipidemia
Jacobson, T. A., & Zimmerman, F. H. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05278.x · Cited by 82
Pozzi, A., Popescu, V., Yang, S., Mei, S., Shi, M., Puolitaival, S. M., Caprioli, R. M., & Capdevila, J. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081554 · Cited by 83
Holman, R. R., Paul, S., Farmer, A., Tucker, L., Stratton, I. M., Neil, H. A. W., & on behalf of the AFORRD study group (2009) · Diabetologia · doi:10.1007/s00125-008-1179-5 · Cited by 81
Fibrates in the Treatment of Dyslipidemias — Time for a Reassessment
Goldfine, A. B., Kaul, S., & Hiatt, W. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1106688 · Cited by 81
Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 81
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies
Revilla, G., Cedó, L., Tondo, M., Moral, A., Pérez, J. I., Corcoy, R., Lerma, E., Fusté, V., Reddy, S. T., Blanco‐Vaca, F., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.012 · Cited by 81
GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M. J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-4-71-99 · Cited by 81
WEINTRAUB, H. S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.041 · Cited by 82
Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus
Pérez, A., Wägner, A. M., Carreras, G., Giménez‐Pérez, G., Sánchez‐Quesada, J. L., Rigla, M., Gómez-Gerique, J. A., Pou, J. M., & de Leiva, A. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.18.2756 · Cited by 81
Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance
Haffner, S. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02634-6 · Cited by 82
PPAR agonists in the treatment of atherosclerosis
Francis, G. A. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00014-6 · Cited by 81
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1297 · Cited by 81
Triggers of acute coronary syndromes
Servoss, S. J., Januzzi, J. L., & Muller, J. E. (2002) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2002.123470 · Cited by 82
Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy
Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81
Derosa, G., Cicero, A. F. G., Bertone, G., Piccinni, M. N., Ciccarelli, L., & Roggeri, D. P. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.10.008 · Cited by 81
Raterman, H. G., Levels, H., Voskuyl, A. E., Lems, W. F., Dijkmans, B. A. C., & Nurmohamed, M. T. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201228 · Cited by 80
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial
Ginsberg, H. N. (2011) · Diabetes Care · doi:10.2337/dc11-s203 · Cited by 80
Lipid Management in Type 2 Diabetes
Solano, M. P., & Goldberg, R. B. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.1.27 · Cited by 82
Diabetes & coronary heart disease: Current perspectives
Ali, M. K., Narayan, K. M. V., & Tandon, N. (2010) · The Indian Journal of Medical Research · doi:10.4103/ijmr.2010_132_05_584 · Cited by 82
Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction
Han, S. H., Quon, M. J., & Koh, K. K. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328012b627 · Cited by 80
Nakamachi, T., Nomiyama, T., Gizard, F., Heywood, E. B., Jones, K. L., Zhao, Y., Fuentes, L., Takebayashi, K., Aso, Y., Staels, B., et al. (2007) · Diabetes · doi:10.2337/db06-1177 · Cited by 80
Pontrelli, L., Parris, W. E., Adeli, K., & Cheung, R. C. (2002) · Metabolism · doi:10.1053/meta.2002.30510 · Cited by 80
Korstanje, R., Li, R., Howard, T. D., Kelmenson, P. M., Marshall, J. D., Paigen, B. J., & Churchill, G. A. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300460-jlr200 · Cited by 80
The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
Ginsberg, H. N., & Stalenhoef, A. F. H. (2003) · Journal of Cardiovascular Risk · doi:10.1097/00043798-200304000-00007 · Cited by 80
Guidelines on the management of stable angina pectoris
Skalidis, E. I., & Vardas, P. E. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl257 · Cited by 80
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 83
Rondanelli, M., Giacosa, A., Opizzi, A., Faliva, M. A., Sala, P., Perna, S., Riva, A., Morazzoni, P., & Bombardelli, E. (2012) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2012.700920 · Cited by 79
Arakawa, R., Tamehiro, N., Nishimaki‐Mogami, T., Ueda, K., & Yokoyama, S. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000163844.07815.c4 · Cited by 79
High-Density Lipoprotein Metabolism: Potential Therapeutic Targets
Davidson, M. H., & Toth, P. P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.011 · Cited by 79
DIABETES MELLITUS AND CORONARY HEART DISEASE
Wilson, P. W. F. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70219-x · Cited by 81
Clinical Impact of a Pharmacist‐Managed Diabetes Mellitus Drug Therapy Management Service
McCord, A. D. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.2.248 · Cited by 79
Araki, M., Nakagawa, Y., Oishi, A., Han, S., Wang, Y., Kumagai, K., Ohno, H., Mizunoe, Y., IWASAKI, H. O., Sekiya, M., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072148 · Cited by 82
Chakrabarti, R., Vikramadithyan, R. K., Misra, P., Hiriyan, J., Raichur, S., Damarla, R. K. B., Gershome, C., Suresh, J., & Rajagopalan, R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705463 · Cited by 79
HDL Cholesterol: Physiology, Pathophysiology, and Management
Link, J. J., Rohatgi, A. K., & de Lemos, J. A. (2007) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2007.01.004 · Cited by 81
Management of Dyslipidemia in Diabetes
Solano, M. P., & Goldberg, R. B. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000188034.76283.5e · Cited by 79
Guo, J., Bei, W., Hu, Y., Tang, C., He, W., Liu, X., Huang, L., Cao, Y., Hu, X., Zhong, X., et al. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.03.012 · Cited by 78
Shi, G. Q., Dropinski, J. F., McKeever, B. M., Xu, S., Becker, J. W., Berger, J. P., MacNaul, K. L., Elbrecht, A., Zhou, G., Doebber, T. W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0502135 · Cited by 79
Fenofibrate Reduces Atherogenesis in ApoE*3Leiden Mice
Kooistra, T., Verschuren, L., der Weij, J. D. V.-V., Köenig, W., Toet, K. H., Princen, H. M. G., & Kleemann, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000238348.05028.14 · Cited by 80
Low HDL-C: A secondary target of dyslipidemia therapy
Rosenson, R. S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.12.021 · Cited by 81
Calkin, A. C., Cooper, M. E., Jandeleit-Dahm, K. A. M., & Allen, T. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0102-6 · Cited by 78
Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates
Rezzi, S., Martin, F., Shanmuganayagam, D., Colman, R. J., Nicholson, J. K., & Weindruch, R. H. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.02.008 · Cited by 80
Who needs to care about small, dense low-density lipoproteins?
Rizzo, M., & Berneis, K. K. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01596.x · Cited by 77
Inhibition of melanoma metastases by fenofibrate
Grabacka, M., Placha, W., Plonka, P. M., Pajak, S., Urbańska, K., Laidler, P. M., & Slominski, A. T. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0479-y · Cited by 77
Bhatt, J., Gopa, B., & Hemavathi, K. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.93857 · Cited by 78
High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
Tuteja, S., & Rader, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.79 · Cited by 77
Management of hypertriglyceridemia.
Oh, R., & Lanier, J. B. (2007) · PubMed · Cited by 77
Trans Fatty Acids and Plasma Lipoproteins
Katan, M. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2000.tb01860.x · Cited by 77
Li, A. C., & Palinski, W. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141247 · Cited by 77
Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction
Amarenco, P. (2001) · Neurology · doi:10.1212/wnl.57.suppl_2.s35 · Cited by 79
Determinants of plasma HDL concentrations and reverse cholesterol transport
Lewis, G. F. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231405.76930.a0 · Cited by 77
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010024 · Cited by 77
Management of Dyslipidemia in the Metabolic Syndrome
Ascaso, J. F., Santos, P. G., Mijares, A. H., Mangas, A., Masana, L., Millán, J., Pallardo, L. F., Pedro‐Botet, J., Jiménez, F. P., Pintó, X., et al. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707010-00004 · Cited by 79
Metadata
- Authors
- Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J., & Wittes, J.
- Affiliations
- Boston University (US)
- West Haven Cooperative Studies Program Coordinating Center (US)
- Veterans Health Administration (US)
- Memphis VA Medical Center (US)
- Tufts University (US)
- Minneapolis VA Medical Center (US)
- Statistics Collaborative (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1999-08-05
- Volume
- 341
- Issue
- 6
- Pages
- 410-418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2328529137
- Semantic Scholar
- c59834b2e2f45268e79b64cd3316445882b86f66
- Cited by
- 3,439
- References
- 40
- Citations by year
- 2026: 22 · 2025: 29 · 2024: 38 · 2023: 52 · 2022: 41 · 2021: 44 · 2020: 46 · 2019: 56 · 2018: 54 · 2017: 62 · 2016: 69 · 2015: 80 · 2014: 93 · 2013: 129 · 2012: 114
- FWCI
- 242.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- gemfibrozil, secondary prevention, coronary artery disease, low HDL cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, nonfatal myocardial infarction, coronary heart disease mortality, stroke, fibrates, men
- MeSH terms
- Aged, Hypolipidemic Agents, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Hypolipoproteinemias, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Risk, Triglycerides, Gemfibrozil, Incidence, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
